Showing results (241-250 of 377) with videos related to
Sort By:
Pageof 38
JAMA Network Open|May 4, 2023
Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast CancerRikki A Cannioto, Kristopher M Attwood, Evan W Davis, et al.Journal of Pain and Symptom Management|November 26, 2018
Pretreatment Psychoneurological Symptoms and Their Association With Longitudinal Cognitive Function and Quality of Life in Older Breast Cancer SurvivorsDanielle B Tometich, Brent J Small, Judith E Carroll, et al.Cell Reports|August 25, 2021
Evaluating the impact of age on immune checkpoint therapy biomarkersRossin Erbe, Zheyu Wang, Sharon Wu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2019
Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)Christine B Ambrosone, Gary R Zirpoli, Alan D Hutson, et al.Cancer|December 21, 2019
Symptom burden among older breast cancer survivors: The Thinking and Living With Cancer (TLC) studyJeanne S Mandelblatt, Wanting Zhai, Jaeil Ahn, et al.Breast Cancer Research and Treatment|May 19, 2022
Association of markers of tumor aggressivity and cognition in women with breast cancer before adjuvant treatment: The Thinking and Living with Cancer StudyJames C Root, Xingtao Zhou, Jaeil Ahn, et al.Journal of the National Cancer Institute|April 3, 2020
Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With SurvivalRikki A Cannioto, Alan Hutson, Shruti Dighe, et al.Cancer|September 26, 2019
Sleep disturbance and neurocognitive outcomes in older patients with breast cancer: Interaction with genotypeJudith E Carroll, Brent J Small, Danielle B Tometich, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2013
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumabLee S Schwartzberg, Kurt W Tauer, Robert C Hermann, et al.Breast Cancer Research and Treatment|October 15, 2014
Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriersXinglei Chai, Tara M Friebel, Christian F Singer, et al.Pageof 38